Table 1 Baseline demographics and clinical characteristics
Number of patients | % | |
|---|---|---|
Age, years | ||
Median | 63 | |
Range | 39–83 | |
Sex | ||
Male | 8 | 80 |
Female | 2 | 20 |
Primary tumor | ||
Colon | 2 | 20 |
Rectum | 8 | 80 |
Extrahepatic disease | ||
Present | 10 | 100 |
Absent | 0 | 0 |
Number of prior chemotherapy lines | ||
1 | 1 | 10 |
2 | 3 | 30 |
3 | 3 | 30 |
4 | 3 | 30 |
Prior chemotherapy regimen | ||
Oxaliplatin | 9 | 90 |
Irinotecan | 8 | 80 |
Bevacizumab | 10 | 100 |
Cetuximab | 1 | 10 |
Panitumumab | 4 | 40 |
TAS-102 | 3 | 30 |
RAS status | ||
Wild | 5 | 50 |
Mutation | 5 | 50 |